Asset Details
Do you wish to reserve the book?
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
Do you wish to request the book?
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
2023
Overview
Amyotrophic lateral sclerosis (ALS) is a poorly treated multifactorial neurodegenerative disease associated with multiple cell types and subcellular organelles. As with other multifactorial diseases, it is likely that drugs will need to target multiple disease processes and cell types to be effective. We review here the role of Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) signalling in ALS, confirm the association of this signalling with fundamental ALS disease processes using the BenevolentAI Knowledge Graph, and demonstrate that inhibitors of this pathway could reduce the ALS pathophysiology in neurons, glia, muscle fibres, and blood cells. Specifically, we suggest that inhibition of the JAK enzymes by approved inhibitors known as Jakinibs could reduce STAT3 activation and modify the progress of this disease. Analysis of the Jakinibs highlights baricitinib as a suitable candidate due to its ability to penetrate the central nervous system and exert beneficial effects on the immune system. Therefore, we recommend that this drug be tested in appropriately designed clinical trials for ALS.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Amyotrophic Lateral Sclerosis - drug therapy
/ Amyotrophic Lateral Sclerosis - genetics
/ Amyotrophic Lateral Sclerosis - metabolism
/ Atrophy
/ Biomedical and Life Sciences
/ Central Nervous System - metabolism
/ COVID-19
/ Disease
/ Drugs
/ Humans
/ Janus Kinase Inhibitors - therapeutic use
/ Janus Kinases - therapeutic use
/ Kinases
/ Mutation
/ Proteins
/ Review
/ STAT3
